From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

European Journal of Haematology

Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry

Leukemia

LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Scientific Reports

Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients

Blood

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report

Frontiers in Oncology

Advancements in microenvironment-based therapies: Transforming the landscape of multiple myeloma treatment

Japanese Journal of Radiology

Review of whole-body magnetic resonance imaging in multiple myeloma

The Oncologist

Physical activity and exercise motivation of multiple myeloma patients: a prospective cross-sectional study

Cancer Immunology, Immunotherapy

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

European Journal of Haematology

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

Journal of Clinical Oncology

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Cancer Science

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Blood

Financial toxicity and time toxicity in multiple myeloma: Prevalence, predictors, and impact on QOL

Oncology

Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors

New England Journal of Medicine

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

JAMA Network Open

Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma

Nature Reviews Clinical Oncology

Long-term outcomes following CAR T cell therapy: What we know so far

Blood Cancer Journal

Addressing the disparities: The approach to the African American patient with multiple myeloma

Journal of Neurosurgery

CyberKnife stereotactic radiosurgery for extramedullary plasmacytoma in the external auditory canal: illustrative case

CancerNetwork

Bispecific antibody dose schedules in relapsed/refractory multiple myeloma

Cancers (Basel)

The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review

HemaSphere

P940: An outpatient model for teclistamab step-up dosing administration – Initial experiences at Fox Chase Cancer Center BMT program

The New England Journal of Medicine

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

Blood

Establishment of a clinical pharmacist-led multiple myeloma clinic with collaborative prescribing model at the National Center for Cancer Care and Research in Qatar

VJHemOnc – Video Journal of Hematology & HemOnc

iStopMM: The psychological effects of MGUS screening and changes to clinical presentation of myeloma

Annals of Hematology

Reporting of adverse events of treatment interventions in multiple myeloma: An overview of systematic reviews

Current Oncology

Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse

Scientific Reports

Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: Pooled analysis of three clinical trials

StatPearls

Relapsed and refractory multiple myeloma

Journal of Hematology & Oncology

The association of Agent Orange exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based study of Vietnam War era veterans

Blood Advances (2024) 8 (1): 236–247.

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Blood (2023) 142 (Supplement 1): 4705

Real-world outcomes for relapsed or refractory multiple myeloma patients treated with lenalidomide and daratumumab sparing triplet regimens: a United States retrospective cohort study

Blood (2023) 142 (Supplement 1): 4693

Cell-free DNA from blood or bone marrow as alternatives to bone marrow cells for molecular diagnostics and monitoring of multiple myeloma

Leukemia

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Indian Journal of Cancer

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis

Cureus

Explosive disease progression after single-agent b-cell maturation antigen-targeted treatment in multiple myeloma: A report of three cases in Sheikh Shakhbout Medical City

The Lancet. Haematology

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Journal of Chemotherapy

Varicella zoster virus reactivation reported with isatuximab use

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

European Journal of Haematology

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

Cancers (Basel)

Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

ASCO Daily News

Bispecific antibodies in refractory multiple myeloma: Basics and unanswered questions

Current Oncology

Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse

U.S. Food & Drug Administration

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

Leukemia and Lymphoma

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: A population-based study

Blood Cancer Journal

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study

PR Newswire

U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

ASCO 2023

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood

Increased COVID-19 breakthrough infection risk after SARS-CoV-2 vaccine boosting in patients with plasma cell disorders: A large nationwide Veterans Affairs study

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy

Single Solitary Plasmacytoma to Active Myeloma

A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab